Remdesivir is the only antiviral approved for treatment of persons hospitalized for coronavirus disease 2019 (COVID-19). This supplement presents new information from real-world cohort studies that report reduced mortality in at-risk populations and reduction in readmission for COVID-19 in the Omicron era.
Keywords: COVID-19; antivirals; cohort studies; real-world evidence; remdesivir.